• 1. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Recent Advances in the Study of 1-(3,5-dimethyl-1,2-oxazol-4-yl)methylpiperazine (CAS: 743416-40-2) in Chemical Biology and Pharmaceutical Research

The compound 1-(3,5-dimethyl-1,2-oxazol-4-yl)methylpiperazine (CAS: 743416-40-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, featuring a piperazine moiety linked to a dimethyloxazole ring, exhibits unique physicochemical properties that make it a promising candidate for drug discovery and development. Recent studies have explored its potential as a scaffold for designing novel therapeutic agents, particularly in the areas of central nervous system (CNS) disorders and infectious diseases.

A 2023 study published in the Journal of Medicinal Chemistry investigated the structural-activity relationship (SAR) of derivatives based on this core structure. The researchers systematically modified various functional groups and evaluated their binding affinities to multiple neurotransmitter receptors. The results demonstrated that the 1-(3,5-dimethyl-1,2-oxazol-4-yl)methylpiperazine scaffold shows particular promise for developing selective serotonin receptor modulators, with potential applications in treating depression and anxiety disorders.

In the field of antimicrobial research, a team from the University of Cambridge reported in ACS Infectious Diseases (2024) that derivatives of 743416-40-2 exhibit potent activity against drug-resistant bacterial strains. The study revealed that the compound's unique structure allows it to bypass common resistance mechanisms, particularly in Gram-positive pathogens. Molecular docking studies suggested that the oxazole-piperazine hybrid interacts with novel binding sites on bacterial ribosomes, offering a potential new mechanism of action for antibiotic development.

Pharmacokinetic studies of 1-(3,5-dimethyl-1,2-oxazol-4-yl)methylpiperazine have also shown encouraging results. Research published in Drug Metabolism and Disposition (2023) demonstrated favorable absorption and distribution profiles in rodent models, with good blood-brain barrier penetration - a crucial factor for CNS-targeted therapeutics. The compound displayed a half-life of approximately 8 hours in plasma, suggesting potential for once-daily dosing in clinical applications.

Recent synthetic chemistry advancements have improved the scalability of producing 743416-40-2 and its derivatives. A 2024 Nature Protocols article detailed a novel catalytic system that achieves the coupling of the oxazole and piperazine moieties with 92% yield and excellent stereoselectivity. This methodological breakthrough addresses previous challenges in large-scale production, paving the way for more extensive preclinical evaluation of this compound class.

Looking forward, several pharmaceutical companies have included 1-(3,5-dimethyl-1,2-oxazol-4-yl)methylpiperazine derivatives in their development pipelines. Current clinical trials (Phase I/II) are investigating its potential in neuropathic pain management and as an adjunct therapy for Parkinson's disease. The compound's versatility and the growing body of research supporting its therapeutic potential suggest it will remain an important focus of chemical biology research in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)